Phase I study of intranodal delivery of a plasmid DNA vaccine for patients with Stage IV melanoma

Cancer

Volumn 98, Issue 1, 2003, Pages 144-154

  Tagawa, Scott T ^a   Lee, Peter ^b   Snively, Jolie ^a   Boswell, William ^a   Ounpraseuth, Song ^c   Lee, Sandra ^c   Hickingbottom, Barbara ^c   Smith, John ^d   Johnson, Denise ^b   Weber, Jeffrey S ^a,e  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c CTL Immunotheraputics   (United States)

^d Providence Hospital   (United States)

^e UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Immunotherapy; Lymph node; Melanoma antigen recognized by T cells; Tyrosinase

Indexed keywords

ALPHA INTERFERON; ANGIOGENESIS INHIBITOR; CANCER VACCINE; CISPLATIN; DACARBAZINE; DNA VACCINE; EPITOPE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 2; MONOPHENOL MONOOXYGENASE; PLASMID DNA; SYNCHOTROPE TA2M; TAMOXIFEN; TETRAMER; VINBLASTINE SULFATE;

ADULT; AGED; ANOREXIA; ARTHRALGIA; ARTICLE; BLOOD SAMPLING; BLOOD TOXICITY; BONE RADIOGRAPHY; BONE SCINTISCANNING; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOLOGY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CANNULATION; CATHETER; CHILL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DENDRITIC CELL; DNA VECTOR; DOSE RESPONSE; DRUG DELIVERY SYSTEM; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG MEGADOSE; DRUG TOLERABILITY; EDEMA; ERYTHEMA; FATIGUE; FEMALE; FEVER; GENETIC CODE; HEADACHE; HUMAN; HYPOTENSION; IMMUNOTHERAPY; INGUINAL LYMPH NODE; INJECTION SITE; LYMPH NODE; MALAISE; MALE; MELANOMA; MYALGIA; NAUSEA; NONHUMAN; PAIN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN DETERMINATION; RECOMBINANT PLASMID; RHINORRHEA; SERUM; SIDE EFFECT; STOMATITIS; T LYMPHOCYTE; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; CANCER VACCINES; FEMALE; FLOW CYTOMETRY; HUMANS; LYMPHATIC METASTASIS; MALE; MELANOMA; MIDDLE AGED; PLASMIDS; SKIN NEOPLASMS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VACCINES, DNA;

EID: 0037664871     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.11462     Document Type: Article

References (52)

1. Hsueh, EC, Gupta, RK, Qi, K and Morton, DL: Correlation of specific immune responses with survival in melanoma patients with distant metastases receiving ployvalent melanoma cell vaccine. J Clin Oncol. 1998;16:2913-2920.
2. Rosenberg SA, Yang JC, Schwartzentruber DJ, et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med. 1998;4:321-327.
3. Helling F, Zhang A, Shang A, et al. GM2-KLH conjugate vaccine: increased immunogenicity in melanoma patients after administration with immunological adjuvant QS-21. Cancer Res. 1995;55:2783-2788.
4. Sondak VK, Liu PY, Tuthill RJ, et al. Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: overall results of a randomized trial of the Southwest Oncology Group. J Clin Oncol. 2002;20:2058-2066.
5. Sosman JA, Unger JM, Liu PY, et al. Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: impact of HLA class I antigen expression on outcome. J Clin Oncol. 2002;20:2067-2075.
6. Wolff JA, Malone RW, Williams P, et al. Direct gene transfer into mouse muscle in vivo. Science. 1999;247:1465-1468.
7. Ulmer JB, Donnelly JJ, Parker SE, et al. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science. 1993;259:1745-1749.
8. Ulmer JB, Deck RR, DeWitt CM. Expression of a viral protein by muscle cells in vivo induces protective cell-mediated immunity. Vaccine. 1997;15:839-841.
9. Raz E, Carson DA, Parker SE, et al. Intradermal gene immunization: the possible role of DNA uptake in the induction of cellular immunity to viruses. Proc Natl Acad Sci USA. 1994;91:9519-9523.
10. Donnelly JJ, Ulmer JB, Shiver JW, Liu MA. DNA vaccines. Annu Rev Immunol. 1997;15:617-648.
11. Mincheff M, Tchakarov S, Zoubak S, et al. Naked DNA and adenoviral immunizations for immunotherapy of prostate cancer: a Phase I/II clinical trial. Eur Urol. 2000;38:208-217.
12. Le TP, Coonan KM, Hedstrom RC, et al. Safety, tolerability and humoral immune responses after intramuscular administration of a malaria DNA vaccine to healthy adult volunteers. Vaccine. 2000;18:1893-1901.
13. MacGregor RR, Boyer JD, Ugen KE, et al. First human trial of a DNA-based vaccine for treatment of human immunodeficiency virus type 1 infection: safety and host response. J Infect Dis. 1998;178:92-100.
14. Stopeck AT, Hersh EM, Akporiaye ET. Phase I study of direct gene transfer of an allogeneic histocompatibility antigen, HLA-B7, in patients with metastatic melanoma. J Clin Oncol. 1997;15:341-349.
15. Wang R, Doolan DL, Le TP, et al. Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine. Science. 1998;282:476-480.
16. Calarota S, Bratt G, Nordlund S, et al. Cellular cytotoxic response induced by DNA vaccination in HIV-1-infected patients. Lancet. 1998;351:1320-1325.
17. Huang AY, Golumbek P, Ahmadzadeh M, et al. Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science. 1994;264:961-965.
18. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature. 1998;392:245-252.
19. Doe B, Selby M, Barnett S, et al. Induction of cytotoxic T lymphocytes by intramuscular immunization with plasmid DNA is facilitated by bone marrow-derived cells. Proc Natl Acad Sci USA. 1996;93:8578-8583.
20. Corr M, Lee DJ, Carson DA, Tighe H. Gene vaccination with naked plasmid DNA: mechanism of CTL priming. J Exp Med. 1996;184:1555-1560.
21. Maloy KJ, Erdmann I, Basch V, et al. Intralymphatic immunization enhances DNA vaccination. Proc Natl Acad Sci USA. 2001;98:3299-3303.
22. Faires MB, Bedrosian I, Xu S, et al. Effective immunization to melanoma antigens by intra-nodal injection of mature, CD83(+) dendritic cells [abstract]. Proc Am Soc Clin Oncol. 2000;19:17.
23. Altman J, Moss PAH, Goulder P, et al. Direct visualization and phenotypic analysis of virus-specific T lymphocytes in HIV infected individuals. Science. 1998;274:94-96.
24. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
25. Kundig TM, Bachmann MF, Ohashi PS, et al. On T cell memory: arguments for antigen dependence. Immunol Rev. 1996;150:63-90.
26. Kundig TM, Bachmann MF, Oehen S, et al. On the role of antigen in maintaining cytotoxic T-cell memory. Proc Natl Acad Sci USA. 1996;93:9716-9723.
27. Lambert LA, Gibson GR, Maloney M, Durell B, Noelle RJ, Barth RJ Jr. Intranodal immunization with tumor lysate-pulsed dendritic cells enhances protective antitumor immunity. Cancer Res. 2001;61:641-646.
28. Jimenez M, Maloy WL, Hearing VJ. Specific identification of an authentic clone for mammalian tyrosinase. J Biol Chem. 1989;264:3397-3403.
29. Wolfel T, Van Pel A, Brichard V, et al. Two tyrosinase nonpeptides recognized on HLA-A2 melanomas by autologous cytolytic T lymphocytes. Eur J Immunol. 1994;24:759-764.
30. Chen YT, Stockert E, Tsang S, et al. Immunophenotyping of melanomas for tyrosinase: implications for vaccine development. Proc Natl Acad Sci USA. 1995;92:8125-8129.
31. Skipper JCA, Hendrickson RC, Gulden PH, et al. An HLA-A2 restricted tyrosinase antigen on melanoma cells results from post-translational modification and suggests a novel processing pathway for membrane proteins. J Exp Med. 1996;183:527-534.
32. Valmori D, Pittet MJ, Vonarbourg C, et al. Analysis of the cytolytic T lymphocyte response of melanoma patients to the naturally HLA-A*0201-associated tyrosinase peptide 368-376. Cancer Res. 1999;59:4050-4055.
33. Spagnoli GC, Schaefer C, Willimann TE, et al. Peptide-specific CTL in tumor infiltrating lymphocytes from metastatic melanomas expressing MART-1/Melan-A, gp100 and tyrosinase genes: a study in an unselected group of HLA-A2.1-positive patients. Int J Cancer. 1995;64:309-315.
34. Jager E, Ringhoffer M, Arand M. Cytolytic T cell reactivity against melanoma-associated differentiation antigens in peripheral blood of melanoma patients and healthy individuals. Melanoma Res. 1996;6:419-425.
35. Lambert LA, Gibson GR, Maloney M, et al. Intranodal immunization with tumor lysate-pulsed dendritic cells enhances protective antitumor immunity. Cancer Res. 2001;61:614-646.
36. Nestle FO, Iijagic S, Gilliet M, et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med. 1998;4:328-332.
37. Wolfel C, Drexler I, Van Pel A, et al. Transporter (TAP)- and proteasome-independent presentation of a melanoma-associated tyrosinase epitope. Int J Cancer. 2000;88:432-438.
38. Riley JP, Rosenberg SA, Parkhurst MR. Identification of a new shared HLA-A2*1 restricted epitope from the melanoma antigen tyrosinase. J Immunother. 2001;24:212-220.
39. Mitchell MS, Darrah D, Yeung D, et al. Phase I trial of adoptive immunotherapy with cytolytic T lymphocytes immunized against a tyrosinase epitope. J Clin Oncol. 2002;20:1075-1086.
40. Bullock TN, Mullins DW, Colella TA, et al. Manipulation of avidity to improve effectiveness of adoptively transferred CD8(+) T cells for melanoma immunotherapy in human MHC class I-transgenic mice. J Immunol. 2001;167:5824-5831.
41. Rubio-Godoy V, Pinilla C, Dutoit V, et al. Toward synthetic combinatorial peptide libraries in positional scanning format (PS-SCL)-based identification of CD8(+) tumor-reactive T-cell ligands: a comparative analysis of PS-SCL recognition by a single tumor-reactive CD8(+) cytolytic T-lymphocyte clone. Cancer Res. 2002;62:2058-2063.
42. Scheibenbogen C, Sun Y, Keilholz U, et al. Identification of known and novel immunogenic T-cell epitopes from tumor antigens recognized by peripheral blood T cells from patients responding to IL-2 based treatment. Int J Cancer. 2002;98:409-414.
43. Balch CM, Buzaid AC, Soong S-J, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol. 2001;19:3635-3648.
44. Balch CM, Soong S-J, Gershenwald JE, et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol. 2001;19:3622-3634.
45. McDermott DF, Mier JW, Lawrence DP, et al. A Phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin 2, and metastatic melanoma. Clin Cancer Res. 2000;6:2201-2208.
46. Flaherty LE, Atkins M, Sosman J, et al. Outpatient biochemotherapy with interleukin-2 and interferon in patients with metastatic malignant melanoma: results of two Phase II cytokine working group trials. J Clin Oncol. 2001;19:3194-3202.
47. O'Day SJ, Gammon G, Boasberg PD, et al. Advantages of concurrent biochemotherapy modified by decrescendo interleukin-2, granulocyte colony-stimulating factor, and tamoxifen for patients with metastatic melanoma. J Clin Oncol. 1999;17:2752-2761.
48. Wang F, Bade E, Kuniyoshi C, et al. Phase I trial of a MART-1 peptide vaccine with incomplete Freund's adjuvant for resected high-risk melanoma. Clin Cancer Res. 1999;5:2756-2765.
49. Schuler-Thurner B, Dieckmann D, Keikavoussi P, et al. Mage-3 and influenza-matrix peptide-specific cytotoxic T cells are inducible in terminal stage HLA-A2.1 + melanoma patients by mature monocyte-derived dendritic cells. J Immunol. 2000;165:3492-3496.
50. Tsioulias GJ, Gupta RK, Tisman G, et al. Serum TA90 antigen-antibody complex as a surrogate marker for the efficacy of a polyvalent allogeneic whole-cell vaccine (CancerVax) in melanoma. Ann Surg Oncol. 2001;8:198-203.
51. Cormier JN, Salgaller ML, Prevette T, et al. Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melan A. Cancer J Sci Am. 1997;3:37-44.
52. Pittet MJ, Speiser DE, Lienard D, et al. Expansion and functional maturation of human tumor antigen-specific CD8+ T cells after vaccination with antigenic peptide. Clin Cancer Res. 2001;7(Suppl):796s-803s.